Huge advantage with ANGPTL3 inhibitor for HoFH patients with minimal to zero LDLR activity

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Small interfering RNA against PCSK9 reduces LDL-c in HeFH independent of genotype
Small interfering RNA against PCSK9 reduces LDL-c in HeFH independent of genotype
EAS 2020
Small interfering RNA against PCSK9 reduces LDL-c in HeFH independent of genotype
- Prof. Frederick Raal
A novel small binding protein that targets PCSK9
A novel small binding protein that targets PCSK9
EAS 2020
A novel small binding protein that targets PCSK9
- Evan Stein, MD, PhD